Even if the recent combinatorial regimen of HER2 antibody plus PD-L1 antibody with chemotherapy showed favorable clinical results in unresectable and metastatic GC patients, the median duration of the response is just 1.1 months longer than the regimen without PD-L1 antibody [4, 5]. Here, ERBB2 is linked to gastric cancer.